Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?Zacks Investment Research • 03/28/24
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24GlobeNewsWire • 03/25/24
U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseBusiness Wire • 03/22/24
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseGlobeNewsWire • 03/22/24
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular EventsGlobeNewsWire • 03/22/24
A Relief Earnings Report Ahead Of An Inflection Point For Esperion TherapeuticsSeeking Alpha • 02/28/24
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/27/24
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27GlobeNewsWire • 02/13/24
This late-January stock-trading pattern has been a winner in 30 of the past 38 yearsMarket Watch • 01/25/24
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 01/23/24
Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment ConsiderationsSeeking Alpha • 01/22/24
Esperion resolves legal dispute with Daiichi Sankyo ahead of likely European drug approvalProactive Investors • 01/03/24
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending LitigationBusiness Wire • 01/03/24
FDA Updates Labels of Esperion's (ESPR) Cholesterol-Lowering DrugsZacks Investment Research • 12/14/23
U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) TabletGlobeNewsWire • 12/13/23